$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs

$pirs Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000143774923013687 Filed on May 11, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$20.06M	$1.936M	$10.99M
YoY Change	442.32%	-82.38%	-29.71%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.664M	$4.023M	$4.379M
YoY Change	-10.22%	-8.13%	6.03%
% of Gross Profit
Research & Development	$14.33M	$13.42M	$14.07M
YoY Change	19.93%	-4.56%	-15.07%
% of Gross Profit
Depreciation & Amortization	$758.0K	$605.0K	$845.0K
YoY Change	30.02%	-28.4%	34.13%
% of Gross Profit
Operating Expenses	$17.99M	$17.45M	$18.45M
YoY Change	12.25%	-5.41%	-10.86%
Operating Profit	$2.063M	-$15.51M	-$7.457M
YoY Change	-116.73%	108.01%	47.4%
Interest Expense	$490.0K	$357.0K	-$3.000K
YoY Change	271.21%	-12000.0%	-200.0%
% of Operating Profit	23.75%
Other Income/Expense, Net	-$161.0K	-$57.00K	$229.0K
YoY Change	-123.82%	-124.89%	-74.1%
Pretax Income	$3.976M	-$13.18M	-$5.101M
YoY Change	-138.46%	158.44%	22.33%
Income Tax
% Of Pretax Income
Net Earnings	$3.976M	-$13.20M	-$5.100M
YoY Change	-138.6%	158.82%	21.43%
Net Earnings / Revenue	19.83%	-681.82%	-46.41%
Basic Earnings Per Share	$0.05	-$0.18	-$0.07
Diluted Earnings Per Share	$0.05	-$0.18	-$0.07
COMMON SHARES
Basic Shares Outstanding	82.02M	74.52M	73.71M shares
Diluted Shares Outstanding	87.83M		73.71M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$54.88M	$48.38M	$100.3M
YoY Change	-32.2%	-51.75%	50.1%
Cash & Equivalents	$44.94M	$39.74M	$83.74M
Short-Term Investments	$9.937M	$8.637M	$16.53M
Other Short-Term Assets	$10.65M	$11.07M	$9.837M
YoY Change	22.3%	12.54%	75.66%
Inventory
Prepaid Expenses
Receivables	$952.0K	$1.055M	$1.644M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$66.47M	$60.51M	$111.7M
YoY Change	-26.88%	-45.86%	26.6%
LONG-TERM ASSETS
Property, Plant & Equipment	$16.16M	$16.71M	$18.85M
YoY Change	-7.27%	-11.37%	-8.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.093M	$1.251M	$2.673M
YoY Change	-53.65%	-53.2%	-16.81%
Total Long-Term Assets	$21.07M	$21.75M	$25.37M
YoY Change	-9.97%	-14.24%	-7.81%
TOTAL ASSETS
Total Short-Term Assets	$66.47M	$60.51M	$111.7M
Total Long-Term Assets	$21.07M	$21.75M	$25.37M
Total Assets	$87.54M	$82.26M	$137.1M
YoY Change	-23.41%	-40.01%	18.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.604M	$5.833M	$4.496M
YoY Change	300.63%	29.74%	29.68%
Accrued Expenses	$8.585M	$9.764M	$11.86M
YoY Change	-15.63%	-17.66%	24.01%
Deferred Revenue	$17.68M	$26.69M	$20.91M
YoY Change	-22.66%	27.61%	21.33%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$34.37M	$42.88M	$39.48M
YoY Change	-3.31%	8.59%	30.46%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$23.93M	$44.18M
YoY Change	-100.0%	-45.85%
Total Long-Term Liabilities	$0.00	$23.93M	$44.18M
YoY Change	-100.0%	-45.85%
TOTAL LIABILITIES
Total Short-Term Liabilities	$34.37M	$42.88M	$39.48M
Total Long-Term Liabilities	$0.00	$23.93M	$44.18M
Total Liabilities	$47.05M	$66.80M	$83.67M
YoY Change	-32.74%	-20.16%	7.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$299.6M	-$303.6M	-$262.2M
YoY Change	9.9%	15.79%	21.61%
Common Stock	$99.00K	$74.00K	$314.7M
YoY Change	-99.97%	-99.98%	24.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$40.50M	$15.46M	$53.45M
YoY Change
Total Liabilities & Shareholders Equity	$87.54M	$82.26M	$137.1M
YoY Change	-23.41%	-40.01%	18.42%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	$3.976M	-$13.20M	-$5.100M
YoY Change	-138.6%	158.82%	21.43%
Depreciation, Depletion And Amortization	$758.0K	$605.0K	$845.0K
YoY Change	30.02%	-28.4%	34.13%
Cash From Operating Activities	-$13.43M	-$11.00M	-$22.64M
YoY Change	-13.78%	-51.44%	86.55%
INVESTING ACTIVITIES
Capital Expenditures	$67.00K	$48.00K	$389.0K
YoY Change	-110.65%	-87.66%	1289.29%
Acquisitions
YoY Change
Other Investing Activities	-$1.299M	$11.95M	-$16.56M
YoY Change	-87.31%	-172.17%
Cash From Investing Activities	-$1.366M	$11.90M	-$16.95M
YoY Change	-87.43%	-170.23%	60428.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$6.473M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	19.78M	$0.00	$6.558M
YoY Change	6939.5%	-100.0%	-32.34%
NET CHANGE
Cash From Operating Activities	-13.43M	-$11.00M	-$22.64M
Cash From Investing Activities	-1.366M	$11.90M	-$16.95M
Cash From Financing Activities	19.78M	$0.00	$6.558M
Net Change In Cash	4.984M	$1.107M	-$34.03M
YoY Change	-119.05%	-103.25%	844.93%
FREE CASH FLOW
Cash From Operating Activities	-$13.43M	-$11.00M	-$22.64M
Capital Expenditures	$67.00K	$48.00K	$389.0K
Free Cash Flow	-$13.50M	-$11.04M	-$23.03M
YoY Change	-9.71%	-52.05%	89.31%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74519103
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74519103
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74519103
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q1	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	2130000	usd
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	15617
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	15617
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	15617
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	us-gaap	Assets Current AssetsCurrent	60505000	usd
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-37471
CY2022Q4	us-gaap	Assets Current AssetsCurrent	73424000	usd
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	30-0784346
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	225 Franklin Street, 26th Floor
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Boston
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02110
CY2023Q1	dei	City Area Code CityAreaCode	857
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	246-8998
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16706000	usd
CY2023Q1	dei	Trading Symbol TradingSymbol	PIRS
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	82019103
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39742000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38635000	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	8637000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	20534000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1055000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5810000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11071000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8445000	usd
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2021Q2	us-gaap	Grants Receivable GrantsReceivable	14200000	eur
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16992000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3796000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3705000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1251000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1369000	usd
CY2023Q1	us-gaap	Assets Assets	82258000	usd
CY2022Q4	us-gaap	Assets Assets	95490000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	5833000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4154000	usd
CY2023Q1	pirs	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	10354000	usd
CY2022Q4	pirs	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	11605000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	26688000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	20824000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	42875000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	36583000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	11727000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	18734000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12198000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12244000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	66800000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	67561000	usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	74000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	74000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	319414000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	318530000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-426000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-254000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-303604000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-290421000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	15458000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	27929000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	82258000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	95490000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2010000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	11180000	usd
CY2023Q1	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	-74000	usd
CY2022Q1	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	-192000	usd
CY2023Q1	us-gaap	Revenues Revenues	1936000	usd
CY2022Q1	us-gaap	Revenues Revenues	10988000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13424000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14066000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4023000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4379000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	17447000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	18445000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15511000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7457000	usd
CY2023Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	357000	usd
CY2022Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-3000	usd
CY2023Q1	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	2028000	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	85000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-57000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	229000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13183000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5101000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-242000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	143000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	70000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-19000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13355000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4977000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74519000
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73711000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	50755000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5101000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	143000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-19000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1178000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	85000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	27929000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13183000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-242000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	70000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	884000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	15458000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13183000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5101000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	605000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	845000	usd
CY2023Q1	pirs	Operating Lease Right Of Use Asset Accretion OperatingLeaseRightOfUseAssetAccretion	34000	usd
CY2022Q1	pirs	Operating Lease Right Of Use Asset Accretion OperatingLeaseRightOfUseAssetAccretion	5000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	884000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1178000	usd
CY2023Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-53000	usd
CY2022Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-0	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-72000	usd
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-91000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	-607000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	19651000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10996000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22643000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	48000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	389000	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	13495000	usd
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1544000	usd
CY2022Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	16559000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	11903000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16948000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6473000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2022Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	10600000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6558000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	200000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-994000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1107000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-34027000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	38635000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	117764000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	39742000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	83737000	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	70000	usd
CY2022Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-19000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	16000	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	298000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	48400000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13200000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5100000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-303600000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Basis of Presentation and Use of Estimates</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying condensed consolidated financial statements of Pieris Pharmaceuticals, Inc. and its wholly-owned subsidiaries were prepared in accordance with U.S. GAAP. The condensed consolidated financial statements include the accounts of all subsidiaries. All intercompany balances and transactions have been eliminated.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates are used for, but are <em style="font: inherit;">not</em> limited to, revenue recognition; deferred tax assets, deferred tax liabilities and valuation allowances; determination of the incremental borrowing rate to calculate right-of-use assets and lease liabilities; beneficial conversion features; fair value of stock options, preferred stock, and warrants; and prepaid and accrued clinical trial expenses. Management evaluates its estimates on an ongoing basis. Actual results and outcomes could differ materially from management’s estimates, judgments and assumptions.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Concentration of Credit Risk and Off-Balance Sheet Risk</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has <em style="font: inherit;">no</em> financial instruments with off-balance sheet risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. Financial instruments that subject Pieris to concentrations of credit risk include cash and cash equivalents, investments, and accounts receivable. The Company’s cash, cash equivalents, and investments are held in accounts with financial institutions that management believes are creditworthy. The Company’s investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimize the exposure to concentration of credit risk. The Company has <em style="font: inherit;">not</em> experienced any credit losses in such accounts and does <em style="font: inherit;">not</em> believe it is exposed to any significant credit risk on these funds. Accounts receivable primarily consist of amounts due under strategic partnership and other license agreements with major multi-national pharmaceutical companies for which the Company does <em style="font: inherit;">not</em> obtain collateral.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"/>
CY2023Q1	us-gaap	Revenues Revenues	1936000	usd
CY2022Q1	us-gaap	Revenues Revenues	10988000	usd
CY2017Q2	pirs	Number Of Technology Licenses NumberOfTechnologyLicenses	5	pure
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1700000	usd
CY2021Q2	us-gaap	Grants Receivable GrantsReceivable	17000000.0	usd
CY2023Q1	pirs	Cash Equivalents And Investments CashEquivalentsAndInvestments	35646000	usd
CY2022Q4	pirs	Cash Equivalents And Investments CashEquivalentsAndInvestments	38152000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	8640000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	8637000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-100000	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	26680000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	26639000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9974000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9647000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16706000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16992000	usd
CY2023Q1	pirs	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	5082000	usd
CY2022Q4	pirs	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	5758000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1677000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3015000	usd
CY2023Q1	pirs	Accrued License Obligations Current AccruedLicenseObligationsCurrent	278000	usd
CY2022Q4	pirs	Accrued License Obligations Current AccruedLicenseObligationsCurrent	245000	usd
CY2023Q1	pirs	Accrued Accounts Payable Current AccruedAccountsPayableCurrent	1837000	usd
CY2022Q4	pirs	Accrued Accounts Payable Current AccruedAccountsPayableCurrent	1245000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	590000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	483000	usd
CY2023Q1	pirs	Accrued Collaboration Costs Current AccruedCollaborationCostsCurrent	0	usd
CY2022Q4	pirs	Accrued Collaboration Costs Current AccruedCollaborationCostsCurrent	0	usd
CY2023Q1	pirs	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	10354000	usd
CY2022Q4	pirs	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	11605000	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	40900000
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	39400000
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74519103
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	15617
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	288000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	349000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	186000	usd
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	159000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	474000	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	508000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y3M18D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.105	pure
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	500000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	600000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1611000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2148000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2148000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2148000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2148000	usd
CY2023Q1	pirs	Lessee Operating Lease Liability To Be Paid Due After Year Four LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour	9846000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	20049000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6963000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	13086000	usd

Files In Submission

Name	View Source	Status
0001437749-23-013687-index-headers.html	Edgar Link	pending
0001437749-23-013687-index.html	Edgar Link	pending
0001437749-23-013687.txt	Edgar Link	pending
0001437749-23-013687-xbrl.zip	Edgar Link	pending
ex_468622.htm	Edgar Link	pending
ex_468623.htm	Edgar Link	pending
ex_468624.htm	Edgar Link	pending
ex_468625.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pirs-20230331.xsd	Edgar Link	pending
pirs20230331_10q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pirs-20230331_cal.xml	Edgar Link	unprocessable
pirs-20230331_lab.xml	Edgar Link	unprocessable
pirs-20230331_def.xml	Edgar Link	unprocessable
pirs-20230331_pre.xml	Edgar Link	unprocessable
pirs20230331_10q_htm.xml	Edgar Link	completed
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs

2023 Q2 Form 10-Q Financial Statement

#000143774923013687 Filed on May 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIRS PIERIS PHARMACEUTICALS, INC. Stock $pirs

2023 Q2 Form 10-Q Financial Statement

#000143774923013687 Filed on May 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs